Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02179671 |
Title | Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer |
Recruitment | Completed |
Gender | |
Phase | Phase II |
Variant Requirements | No |
Sponsors | AstraZeneca |
Indications | |
Therapies | |
Age Groups: | |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Research Site | Goodyear | Arizona | 85338 | United States | Details | |
Research Site | Washington | District of Columbia | 20007 | United States | Details | |
Research Site | Augusta | Georgia | 30912 | United States | Details | |
Research Site | Marietta | Georgia | 30060 | United States | Details | |
Research Site | Ashland | Kentucky | 41101 | United States | Details | |
Research Site | Saint Louis | Missouri | 63110 | United States | Details | |
Research Site | Mineola | New York | 11501 | United States | Details | |
Research Site | Huntersville | North Carolina | 28078 | United States | Details | |
Research Site | Spokane | Washington | 99208-1129 | United States | Details | |
Research Site | Tacoma | Washington | 98405 | United States | Details |